Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAINS study of bevacizumab versus dexamethasone for symptomatic cerebral radiation necrosis
NL-OMON60653Phase 3Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in brain radionecrosis comparing Bevacizumab first-line arm with Dexamethasone first-line arm (2 arms). Primary endpoint: Favourable clinical response at 12 weeks. Started Jul 2025; status: recruiting.
02
Drugs
bevacizumabdexamethasone
03
Conditions
brain radionecrosis
Beyond the preview
Go deeper on NL-OMON60653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60653.